Enanta Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 145
- Market Cap
- $275.6M
- Introduction
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2009-10-08
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 52
- Registration Number
- NCT00990145
- Locations
- 🇺🇸
PPD Phase I Unit, Austin, Texas, United States
Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers
- Conditions
- Skin and Soft Tissue InfectionsMethicillin-resistant Staphylococcus Aureus
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2009-10-06
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 67
- Registration Number
- NCT00989872
- Locations
- 🇺🇸
PPD Phase I Unit, Austin, Texas, United States
Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia
- Conditions
- Community Acquired Pneumonia
- First Posted Date
- 2005-12-28
- Last Posted Date
- 2006-09-19
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 250
- Registration Number
- NCT00270517
- Locations
- 🇺🇸
Enanta Pharmaceuticals, Inc., Watertown, Massachusetts, United States